{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:07:08Z","timestamp":1790935628141,"version":"4.1.0"},"reference-count":31,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2006,8,20]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>A multicenter, single-arm study examining efficacy and toxicity of epratuzumab combined with rituximab was conducted in patients with recurrent or refractory non-Hodgkin's lymphoma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p>Sixty-five patients were enrolled; 34 patients with follicular lymphoma (FL), 15 patients with diffuse large B-cell lymphoma (DLBCL), and 16 patients with other lymphomas. The patients had received a median of two prior therapies (range, 1 to 4); 23% had received rituximab. Epratuzumab was given at 360 mg\/m<jats:sup>2<\/jats:sup>intravenously over 60 minutes followed by infusion of 375 mg\/m<jats:sup>2<\/jats:sup>rituximab, weekly for 4 consecutive weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Combination therapy was well tolerated without greater toxicity than rituximab alone. The objective response (OR) rate was 47% (30 of 64) in assessable patients (46%; 30 of 65 in all patients), being highest in FL (64%; 21 of 33) and DLBCL (47%; seven of 15), and with 24% (eight of 33) and 33% (five of 15) achieving complete response (CR) or complete response unconfirmed (CRu) in these two groups, respectively. Two of six patients with marginal zone lymphoma responded to treatment (one CR). There was a trend for the response rates to be higher in patients with low prognostic index scores (statistically significant with respect to the Follicular Lymphoma International Prognostic Index score in FL patients), with 12 FL patients and three DLBCL patients in groups 0 to 1 having OR (CR\/CRu) rates of 83% (33%) and 100% (100%), respectively. The median duration of response was 16 months for FL, with five patients currently progression free for 18 months to 30 months, and 6 months for DLBCL, with two patients currently progression free for 12 months and 18 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Epratuzumab combined with rituximab was well tolerated, demonstrating promising antilymphoma activity that warrants additional study.<\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2006.05.6291","type":"journal-article","created":{"date-parts":[[2006,7,25]],"date-time":"2006-07-25T00:34:12Z","timestamp":1153787652000},"page":"3880-3886","source":"Crossref","is-referenced-by-count":137,"title":["Multicenter Phase II Trial of Immunotherapy With the Humanized Anti-CD22 Antibody, Epratuzumab, in Combination With Rituximab, in Refractory or Recurrent Non-Hodgkin's Lymphoma"],"prefix":"10.1200","volume":"24","author":[{"given":"Sandra J.","family":"Strauss","sequence":"first","affiliation":[{"name":"From the Cancer Research United Kingdom Medical Oncology Unit, St Bartholomew's Hospital, London, United Kingdom; Service des Maladies du Sang, Lille; Clinique Victor Hugo, Le Mans; Center Hospitalier Lyon-Sud, Lyon, France; University of Erlangen-Nuremberg, Erlangen; University Hospital, Koln; University Hospital, Frankfurt, Germany; Istituto di Ematologica Seragnoli, Bologna, Italy; Immunomedics Inc, Morris Plains; and the Garden State Cancer Center, Center for Molecular Medicine and Immunology,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Morschhauser","sequence":"additional","affiliation":[{"name":"From the Cancer Research United Kingdom Medical Oncology Unit, St Bartholomew's Hospital, London, United Kingdom; Service des Maladies du Sang, Lille; Clinique Victor Hugo, Le Mans; Center Hospitalier Lyon-Sud, Lyon, France; University of Erlangen-Nuremberg, Erlangen; University Hospital, Koln; University Hospital, Frankfurt, Germany; Istituto di Ematologica Seragnoli, Bologna, Italy; Immunomedics Inc, Morris Plains; and the Garden State Cancer Center, Center for Molecular Medicine and Immunology,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juergen","family":"Rech","sequence":"additional","affiliation":[{"name":"From the Cancer Research United Kingdom Medical Oncology Unit, St Bartholomew's Hospital, London, United Kingdom; Service des Maladies du Sang, Lille; Clinique Victor Hugo, Le Mans; Center Hospitalier Lyon-Sud, Lyon, France; University of Erlangen-Nuremberg, Erlangen; University Hospital, Koln; University Hospital, Frankfurt, Germany; Istituto di Ematologica Seragnoli, Bologna, Italy; Immunomedics Inc, Morris Plains; and the Garden State Cancer Center, Center for Molecular Medicine and Immunology,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Repp","sequence":"additional","affiliation":[{"name":"From the Cancer Research United Kingdom Medical Oncology Unit, St Bartholomew's Hospital, London, United Kingdom; Service des Maladies du Sang, Lille; Clinique Victor Hugo, Le Mans; Center Hospitalier Lyon-Sud, Lyon, France; University of Erlangen-Nuremberg, Erlangen; University Hospital, Koln; University Hospital, Frankfurt, Germany; Istituto di Ematologica Seragnoli, Bologna, Italy; Immunomedics Inc, Morris Plains; and the Garden State Cancer Center, Center for Molecular Medicine and Immunology,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Solal-Celigny","sequence":"additional","affiliation":[{"name":"From the Cancer Research United Kingdom Medical Oncology Unit, St Bartholomew's Hospital, London, United Kingdom; Service des Maladies du Sang, Lille; Clinique Victor Hugo, Le Mans; Center Hospitalier Lyon-Sud, Lyon, France; University of Erlangen-Nuremberg, Erlangen; University Hospital, Koln; University Hospital, Frankfurt, Germany; Istituto di Ematologica Seragnoli, Bologna, Italy; Immunomedics Inc, Morris Plains; and the Garden State Cancer Center, Center for Molecular Medicine and Immunology,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier L.","family":"Zinzani","sequence":"additional","affiliation":[{"name":"From the Cancer Research United Kingdom Medical Oncology Unit, St Bartholomew's Hospital, London, United Kingdom; Service des Maladies du Sang, Lille; Clinique Victor Hugo, Le Mans; Center Hospitalier Lyon-Sud, Lyon, France; University of Erlangen-Nuremberg, Erlangen; University Hospital, Koln; University Hospital, Frankfurt, Germany; Istituto di Ematologica Seragnoli, Bologna, Italy; Immunomedics Inc, Morris Plains; and the Garden State Cancer Center, Center for Molecular Medicine and Immunology,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Engert","sequence":"additional","affiliation":[{"name":"From the Cancer Research United Kingdom Medical Oncology Unit, St Bartholomew's Hospital, London, United Kingdom; Service des Maladies du Sang, Lille; Clinique Victor Hugo, Le Mans; Center Hospitalier Lyon-Sud, Lyon, France; University of Erlangen-Nuremberg, Erlangen; University Hospital, Koln; University Hospital, Frankfurt, Germany; Istituto di Ematologica Seragnoli, Bologna, Italy; Immunomedics Inc, Morris Plains; and the Garden State Cancer Center, Center for Molecular Medicine and Immunology,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Coiffier","sequence":"additional","affiliation":[{"name":"From the Cancer Research United Kingdom Medical Oncology Unit, St Bartholomew's Hospital, London, United Kingdom; Service des Maladies du Sang, Lille; Clinique Victor Hugo, Le Mans; Center Hospitalier Lyon-Sud, Lyon, France; University of Erlangen-Nuremberg, Erlangen; University Hospital, Koln; University Hospital, Frankfurt, Germany; Istituto di Ematologica Seragnoli, Bologna, Italy; Immunomedics Inc, Morris Plains; and the Garden State Cancer Center, Center for Molecular Medicine and Immunology,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter F.","family":"Hoelzer","sequence":"additional","affiliation":[{"name":"From the Cancer Research United Kingdom Medical Oncology Unit, St Bartholomew's Hospital, London, United Kingdom; Service des Maladies du Sang, Lille; Clinique Victor Hugo, Le Mans; Center Hospitalier Lyon-Sud, Lyon, France; University of Erlangen-Nuremberg, Erlangen; University Hospital, Koln; University Hospital, Frankfurt, Germany; Istituto di Ematologica Seragnoli, Bologna, Italy; Immunomedics Inc, Morris Plains; and the Garden State Cancer Center, Center for Molecular Medicine and Immunology,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Wegener","sequence":"additional","affiliation":[{"name":"From the Cancer Research United Kingdom Medical Oncology Unit, St Bartholomew's Hospital, London, United Kingdom; Service des Maladies du Sang, Lille; Clinique Victor Hugo, Le Mans; Center Hospitalier Lyon-Sud, Lyon, France; University of Erlangen-Nuremberg, Erlangen; University Hospital, Koln; University Hospital, Frankfurt, Germany; Istituto di Ematologica Seragnoli, Bologna, Italy; Immunomedics Inc, Morris Plains; and the Garden State Cancer Center, Center for Molecular Medicine and Immunology,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick K.W.","family":"Teoh","sequence":"additional","affiliation":[{"name":"From the Cancer Research United Kingdom Medical Oncology Unit, St Bartholomew's Hospital, London, United Kingdom; Service des Maladies du Sang, Lille; Clinique Victor Hugo, Le Mans; Center Hospitalier Lyon-Sud, Lyon, France; University of Erlangen-Nuremberg, Erlangen; University Hospital, Koln; University Hospital, Frankfurt, Germany; Istituto di Ematologica Seragnoli, Bologna, Italy; Immunomedics Inc, Morris Plains; and the Garden State Cancer Center, Center for Molecular Medicine and Immunology,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Goldenberg","sequence":"additional","affiliation":[{"name":"From the Cancer Research United Kingdom Medical Oncology Unit, St Bartholomew's Hospital, London, United Kingdom; Service des Maladies du Sang, Lille; Clinique Victor Hugo, Le Mans; Center Hospitalier Lyon-Sud, Lyon, France; University of Erlangen-Nuremberg, Erlangen; University Hospital, Koln; University Hospital, Frankfurt, Germany; Istituto di Ematologica Seragnoli, Bologna, Italy; Immunomedics Inc, Morris Plains; and the Garden State Cancer Center, Center for Molecular Medicine and Immunology,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. Andrew","family":"Lister","sequence":"additional","affiliation":[{"name":"From the Cancer Research United Kingdom Medical Oncology Unit, St Bartholomew's Hospital, London, United Kingdom; Service des Maladies du Sang, Lille; Clinique Victor Hugo, Le Mans; Center Hospitalier Lyon-Sud, Lyon, France; University of Erlangen-Nuremberg, Erlangen; University Hospital, Koln; University Hospital, Frankfurt, Germany; Istituto di Ematologica Seragnoli, Bologna, Italy; Immunomedics Inc, Morris Plains; and the Garden State Cancer Center, Center for Molecular Medicine and Immunology,..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.11.3909"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.2174\/1389201013378581"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"R4","unstructured":"Coiffier B, Haioun C, Ketterer N, et al: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 92: 1927,1998-1932,"},{"key":"R5","doi-asserted-by":"crossref","unstructured":"Czuczman MS, Weaver R, Alkuzweny B, et al: Prolonged clinical and molecular remissions in patients with low-grade follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow up. J Clin Oncol 23: 4711,2004-4716,","DOI":"10.1200\/JCO.2004.04.020"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"R7","doi-asserted-by":"crossref","unstructured":"Pfreundschuh MG, Tr\u00fcmper L, Ma D, et al: Randomized intergroup trial of first line treatment for patients \u2264 60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab: Early stopping after the first interim analysis. J Clin Oncol 23: 558s,2004, (abstr 6500)","DOI":"10.1200\/jco.2004.22.90140.6500"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2001-12-0276"},{"key":"R9","doi-asserted-by":"crossref","unstructured":"Clark EA: CD22, a B cell-specific receptor, mediates adhesion and signal transduction. J Immunol 150: 4715,1993-4718,","DOI":"10.4049\/jimmunol.150.11.4715"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1038\/384634a0"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1006\/smim.1998.0121"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1038\/ni1072"},{"key":"R13","unstructured":"Pawlak-Byczkowska EJ, Hansen HJ, Dion AS, et al: Two new monoclonal antibodies, EPB-1 and EPB-2, reactive with human lymphoma. Cancer Res 49: 4568,1989-4577,"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1007\/BF01518451"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1016\/0161-5890(95)00080-1"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-01-0128"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0493"},{"key":"R18","unstructured":"Hernandez-Ilizaliturri F, Gada P, Repasky EA, et al: Enhancement in anti-tumor activity of rituximab when combined with epratuzumab or apolizumab (Hu1D10) in a B-cell lymphoma severe combined immunodeficiency (SCID) mouse model. Blood 100: 158a,2002, (abstr 6591)"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.01.082"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0294"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.13.821"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4434"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2846"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.1.140"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.01965.x"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.076"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.17.3135"},{"key":"R31","doi-asserted-by":"crossref","unstructured":"Micallef IN, Kahl BS, Gayko U, et al: Initial results of a pilot study of epratuzumab and rituximab in combination with CHOP chemotherapy (ER-CHOP) in previously untreated patients with diffuse large B-cell lymphoma (DLBCL). J Clin Oncol 23: 577s,2004, (abstr 6580)","DOI":"10.1200\/jco.2004.22.90140.6580"},{"key":"R32","doi-asserted-by":"crossref","unstructured":"Friedberg JW, Leonard JP, Younes A, et al: Updated results from a phase II study of galiximab (anti-CD80) in combination with rituximab for relapsed or refractory, follicular NHL. Blood 106: 685a,2005, (abstr 2435)","DOI":"10.1182\/blood.V106.11.2435.2435"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2006.05.6291","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T06:02:12Z","timestamp":1683525732000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2006.05.6291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8,20]]},"references-count":31,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2006,8,20]]}},"alternative-id":["10.1200\/JCO.2006.05.6291"],"URL":"https:\/\/doi.org\/10.1200\/jco.2006.05.6291","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,8,20]]}}}